A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs Respiratory syncytial virus vaccine-Vaxart (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Vaxart
- 08 May 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 08 May 2017 Planned primary completion date changed from 1 Dec 2016 to 9 Sep 2017.
- 15 Jul 2016 New trial record